{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:24:45Z","timestamp":1790691885363,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Genomics"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hypertrophic scar (HTS) is a fibroproliferative skin disorder characterized by excessive cell proliferation, migration, and extracellular matrix (ECM) deposition. The CUB and Sushi multiple domains 1 (CSMD1) has previously been identified as the key regulatory gene of hypertrophic scar by a large sample GWAS study. However, further research has not yet been conducted to verify this finding in other HTS patients and to determine the underlying mechanism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this study, we verified that CSMD1 was downregulated in both HTS tissue and HTS-derived fibroblasts. The knockdown of CSMD1 resulted in enhanced migration and fibronectin1 (FN1) secretion in fibroblasts in vitro. In addition, the upstream and downstream regulatory mechanisms of CSMD1 were also investigated through microRNA (miRNA) databases screening and RNA-sequencing (RNA-seq) respectively. The screening of four common microRNA (miRNA) databases suggested that miR-190a-3p binds to the CSMD1 and may regulate its expression. We confirmed that miR-190a-3p directly targeted the CSMD1\u20133\u2032-UTR using luciferase reporter assays. Furthermore, the overexpression of miR-190a-3p showed promotion of migratory activity and FN1 secretion in fibroblasts, resembling the effect of CSMD1 knockdown; whereas the knockdown of miR-190a-3p exerted the opposite effect. Finally, transcriptomic analysis showed activation of Janus kinase-signal transducer and activator of transcription (JAK\/STAT) signaling pathway in the CSMD1 knockdown fibroblasts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study has validated the conclusions of the previous GWAS study conducted in Chinese population. In vitro experiments have provided further evidence on the function of CSMD1 in the development of HTS, and have also revealed the underlying upstream and downstream regulating mechanisms. Additionally, the JAK\/STAT signaling pathway identified using RNA-seq might provide a potential treatment approach, especially for HTS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12864-021-07920-8","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T08:03:05Z","timestamp":1628755385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Inhibition of CUB and sushi multiple domains 1 (CSMD1) expression by miRNA-190a-3p enhances hypertrophic scar-derived fibroblast migration in vitro"],"prefix":"10.1186","volume":"22","author":[{"given":"Shuchen","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Khoong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"7920_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(16)31406-4","volume":"388","author":"CC Finnerty","year":"2016","unstructured":"Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P, Herndon DN. Hypertrophic scarring\u00a0: the greatest unmet challenge after burn injury. Lancet. 2016;388:1427\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(16)31406-4.","journal-title":"Lancet."},{"key":"7920_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030606","volume-title":"Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis","author":"R Ogawa","year":"2017","unstructured":"Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis; 2017."},{"key":"7920_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mehy.2008.01.032","volume":"71","author":"S Akaishi","year":"2008","unstructured":"Akaishi S, Ogawa R, Hyakusoku H. Keloid and hypertrophic scar: neurogenic inflammation hypotheses. Med Hypotheses. 2008;71:32\u20138.","journal-title":"Med Hypotheses"},{"key":"7920_CR4","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028\u201340. https:\/\/doi.org\/10.1038\/nm.2807.","journal-title":"Nat Med"},{"key":"7920_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.matbio.2018.01.019","volume":"68\u201369","author":"P Pakshir","year":"2018","unstructured":"Pakshir P, Hinz B. The big five in fibrosis: macrophages, myofibroblasts, matrix, mechanics, and miscommunication. Matrix Biol. 2018;68\u201369:81\u201393. https:\/\/doi.org\/10.1016\/j.matbio.2018.01.019.","journal-title":"Matrix Biol"},{"key":"7920_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2133.2009.09258.x","volume":"161","author":"JJ Brown","year":"2009","unstructured":"Brown JJ, Bayat A. Genetic susceptibility to raised dermal scarring. Br J Dermatol. 2009;161:8\u201318.","journal-title":"Br J Dermatol"},{"key":"7920_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/SLA.0000000000001439","volume":"262","author":"RF Sood","year":"2015","unstructured":"Sood RF, Hocking AM, Muffley LA, Ga M, Honari S, Reiner AP, et al. Genome-wide association study of postburn scarring identifies a novel protective variant. Ann Surg. 2015;262:563\u20139.","journal-title":"Ann Surg"},{"key":"7920_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1006\/geno.2001.6587","volume":"75","author":"PC Sun","year":"2001","unstructured":"Sun PC, Uppaluri R, Schmidt AP, Pashia ME, Quant EC, Sunwoo JB, et al. Transcript map of the 8p23 putative tumor suppressor region. Genomics. 2001;75:17\u201325.","journal-title":"Genomics."},{"key":"7920_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3892\/or.2017.5656","volume":"38","author":"M Kamal","year":"2017","unstructured":"Kamal M, Holliday DL, Morrison EE, Speirs V, Toomes C, Bell SM. Loss of CSMD1 expression disrupts mammary duct formation while enhancing proliferation, migration and invasion. Oncol Rep. 2017;38:283\u201392.","journal-title":"Oncol Rep"},{"key":"7920_CR10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10495-012-0727-0","volume":"17","author":"MR Tang","year":"2012","unstructured":"Tang MR, Wang YX, Guo S, Han SY, Wang D. CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway. Apoptosis. 2012;17:927\u201337.","journal-title":"Apoptosis."},{"key":"7920_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.4161\/cbt.8.10.8132","volume":"8","author":"C Ma","year":"2009","unstructured":"Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, et al. Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther. 2009;8:907\u201316.","journal-title":"Cancer Biol Ther"},{"key":"7920_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrm3838","volume":"15","author":"M Ha","year":"2014","unstructured":"Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7920_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00403-009-1014-y","volume":"302","author":"B Shih","year":"2010","unstructured":"Shih B, Bayat A. Genetics of keloid scarring. Arch Dermatol Res. 2010;302:319\u201339.","journal-title":"Arch Dermatol Res"},{"key":"7920_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/DAD.0b013e31825ba13f","volume":"35","author":"C Huang","year":"2013","unstructured":"Huang C, Nie F, Qin Z, Li B, Zhao X. A snapshot of gene expression signatures generated using microarray datasets associated with excessive scarring. Am J Dermatopathol. 2013;35:64\u201373.","journal-title":"Am J Dermatopathol"},{"key":"7920_CR15","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.0022-202X.2004.22327.x","volume":"122","author":"AG Marneros","year":"2004","unstructured":"Marneros AG, Norris JEC, Watanabe S, Reichenberger E, Olsen BR. Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J Invest Dermatol. 2004;122:1126\u201332. https:\/\/doi.org\/10.1111\/j.0022-202X.2004.22327.x.","journal-title":"J Invest Dermatol"},{"key":"7920_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00403-008-0880-z","volume":"301","author":"M Nassiri","year":"2009","unstructured":"Nassiri M, Woolery-Lloyd H, Ramos S, Jacob SE, Gugic D, Viciana A, et al. Gene expression profiling reveals alteration of caspase 6 and 14 transcripts in normal skin of keloid-prone patients. Arch Dermatol Res. 2009;301:183\u20138.","journal-title":"Arch Dermatol Res"},{"key":"7920_CR17","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/ng.645","volume":"42","author":"M Nakashima","year":"2010","unstructured":"Nakashima M, Chung S, Takahashi A, Kamatani N, Kawaguchi T, Tsunoda T, et al. A genome-wide association study identifies four susceptibility loci for keloid in the japanese population. Nat Genet. 2010;42:768\u201372. https:\/\/doi.org\/10.1038\/ng.645.","journal-title":"Nat Genet"},{"key":"7920_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-12522-w","volume":"10","author":"AS Lee","year":"2019","unstructured":"Lee AS, Rusch J, Lima AC, Usmani A, Huang N, Lepamets M, et al. Rare mutations in the complement regulatory gene CSMD1 are associated with male and female infertility. Nat Commun. 2019;10:1\u201316. https:\/\/doi.org\/10.1038\/s41467-019-12522-w.","journal-title":"Nat Commun"},{"key":"7920_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/hep.22698","volume":"49","author":"Y Midorikawa","year":"2009","unstructured":"Midorikawa Y, Yamamoto S, Tsuji S, Kamimura N, Ishikawa S, Igarashi H, et al. Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology. 2009;49:513\u201322.","journal-title":"Hepatology."},{"key":"7920_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrg2843","volume":"11","author":"J Krol","year":"2010","unstructured":"Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597\u2013610.","journal-title":"Nat Rev Genet"},{"key":"7920_CR21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.biopha.2018.01.158","volume":"100","author":"X Zhou","year":"2018","unstructured":"Zhou X, Xie Y, Xiao H, Deng X, Wang Y, Jiang L, et al. MicroRNA-519d inhibits proliferation and induces apoptosis of human hypertrophic scar fibroblasts through targeting Sirtuin 7. Biomed Pharmacother. 2018;100:184\u201390. https:\/\/doi.org\/10.1016\/j.biopha.2018.01.158.","journal-title":"Biomed Pharmacother"},{"key":"7920_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10735-019-09828-w","volume":"50","author":"T He","year":"2019","unstructured":"He T, Zhang Y, Liu Y, Wang H, Zhang W, Liu J, et al. MicroRNA-494 targets PTEN and suppresses PI3K\/AKT pathway to alleviate hypertrophic scar formation. J Mol Histol. 2019;50:315\u201323.","journal-title":"J Mol Histol"},{"key":"7920_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.yexcr.2017.09.009","volume":"361","author":"X Wang","year":"2017","unstructured":"Wang X, Zhang Y, Jiang BH, Zhang Q, Zhou RP, Zhang L, et al. Study on the role of Hsa-miR-31-5p in hypertrophic scar formation and the mechanism. Exp Cell Res. 2017;361:201\u20139. https:\/\/doi.org\/10.1016\/j.yexcr.2017.09.009.","journal-title":"Exp Cell Res"},{"key":"7920_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203\u201321.","journal-title":"Nat Rev Drug Discov"},{"key":"7920_CR25","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jid.2018.11.007","volume":"139","author":"CL Gallant-Behm","year":"2019","unstructured":"Gallant-Behm CL, Piper J, Lynch JM, Seto AG, Hong SJ, Mustoe TA, et al. A MicroRNA-29 mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin. J Invest Dermatol. 2019;139:1073\u201381. https:\/\/doi.org\/10.1016\/j.jid.2018.11.007.","journal-title":"J Invest Dermatol"},{"key":"7920_CR26","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.7150\/ijbs.23802","volume":"15","author":"XL Chen","year":"2019","unstructured":"Chen XL, Hong LL, Wang KL, Liu X, Wang JL, Lei L, et al. Deregulation of CSMD1 targeted by microRNA-10b drives gastric cancer progression through the NF-\u03baB pathway. Int J Biol Sci. 2019;15:2075\u201386.","journal-title":"Int J Biol Sci"},{"key":"7920_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2801-4","volume":"16","author":"Q Zhu","year":"2016","unstructured":"Zhu Q, Gong L, Wang J, Tu Q, Yao L, Zhang JR, et al. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). BMC Cancer. 2016;16:1\u201310. https:\/\/doi.org\/10.1186\/s12885-016-2801-4.","journal-title":"BMC Cancer"},{"key":"7920_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-019-0984-x","volume":"19","author":"Y Yu","year":"2019","unstructured":"Yu Y, Cao XC. MiR-190-5p in human diseases. Cancer Cell Int. 2019;19:1\u20139. https:\/\/doi.org\/10.1186\/s12935-019-0984-x.","journal-title":"Cancer Cell Int"},{"key":"7920_CR29","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.18632\/aging.101845","volume":"11","author":"L Chu","year":"2019","unstructured":"Chu L, Yu L, Liu J, Song S, Yang H, Han F, et al. Long intergenic non-coding LINC00657 regulates tumorigenesis of glioblastoma by acting as a molecular sponge of miR-190a-3p. Aging (Albany NY). 2019;11:1456\u201370.","journal-title":"Aging (Albany NY)"},{"key":"7920_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.clbc.2020.04.006","volume":"20","author":"S Wang","year":"2020","unstructured":"Wang S, Liu F, Ma H, Cui X, Yang S, Qin R. circCDYL acts as a tumor suppressor in triple negative breast Cancer by sponging miR-190a-3p and upregulating TP53INP1. Clin Breast Cancer. 2020;20:422\u201330. https:\/\/doi.org\/10.1016\/j.clbc.2020.04.006.","journal-title":"Clin Breast Cancer"},{"key":"7920_CR31","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.cell.2020.04.052","volume":"181","author":"AV Villarino","year":"2020","unstructured":"Villarino AV, Gadina M, O\u2019Shea JJ, Kanno Y. SnapShot: Jak-STAT Signaling II. Cell. 2020;181:1696\u20131696.e1. https:\/\/doi.org\/10.1016\/j.cell.2020.04.052.","journal-title":"Cell"},{"key":"7920_CR32","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","volume":"36","author":"JJ O\u2019Shea","year":"2012","unstructured":"O\u2019Shea JJ, Plenge R. JAK and STAT signaling molecules in Immunoregulation and immune-mediated disease. Immunity. 2012;36:542\u201350. https:\/\/doi.org\/10.1016\/j.immuni.2012.03.014.","journal-title":"Immunity."},{"key":"7920_CR33","doi-asserted-by":"publisher","first-page":"6406","DOI":"10.1038\/sj.onc.1208788","volume":"24","author":"Y Niwa","year":"2005","unstructured":"Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK\/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005;24:6406\u201317.","journal-title":"Oncogene."},{"key":"7920_CR34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/wrr.12197","volume":"22","author":"C Huang","year":"2014","unstructured":"Huang C, Ogawa R. The link between hypertension and pathological scarring: does hypertension cause or promote keloid and hypertrophic scar pathogenesis? Wound Repair Regen. 2014;22:462\u20136.","journal-title":"Wound Repair Regen"},{"key":"7920_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16:843\u201362. https:\/\/doi.org\/10.1038\/nrd.2017.201.","journal-title":"Nat Rev Drug Discov"},{"key":"7920_CR36","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.4049\/jimmunol.1901477","volume":"204","author":"M Gadina","year":"2020","unstructured":"Gadina M, Chisolm DA, Philips RL, McInness IB, Changelian PS, O\u2019Shea JJ. Translating JAKs to Jakinibs. J Immunol. 2020;204:2011\u201320.","journal-title":"J Immunol"},{"key":"7920_CR37","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(19)30419-2.","journal-title":"Lancet."},{"key":"7920_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of Filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying Antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315\u201325.","journal-title":"JAMA"}],"container-title":["BMC Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12864-021-07920-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12864-021-07920-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12864-021-07920-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T08:04:30Z","timestamp":1628755470000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgenomics.biomedcentral.com\/articles\/10.1186\/s12864-021-07920-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7920"],"URL":"https:\/\/doi.org\/10.1186\/s12864-021-07920-8","relation":{},"ISSN":["1471-2164"],"issn-type":[{"value":"1471-2164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the institutional ethics board of Shanghai Ninth People\u2019s Hospital Ethics Committee Board, Shanghai Jiaotong University School of Medicine and followed the ethical principles of the Declaration of Helsinki 1964. All patients were well informed about the utilization of specimens and signed written informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"613"}}